OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Sells $7,527,168.00 in Stock

Key Points

• Squadron Capital sold 326,700 OrthoPediatrics shares at an average price of $23.04, generating approximately $7.53 million. The shareholder retained 6.54 million shares, but reduced its ownership by 4.76%.
• OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst expectations for revenue of $68.21 million and a loss of $0.30 per share.
• Analysts maintain a favorable outlook, with nine Buy ratings, a consensus “Moderate Buy” rating and an average price target of $26.44 versus the stock’s recent price near $23.00.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) major shareholder Squadron Capital Llc sold 326,700 shares of the firm's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the transaction, the insider directly owned 6,536,764 shares in the company, valued at $150,607,042.56. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Tuesday, September 1st, Squadron Capital Llc sold 10,131 shares of OrthoPediatrics stock. The shares were sold at an average price of $23.10, for a total value of $234,026.10.
• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total value of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS traded down $0.31 during midday trading on Tuesday, hitting $23.00. The company had a trading volume of 139,797 shares, compared to its average volume of 281,544. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The company has a fifty day moving average of $21.61 and a two-hundred day moving average of $18.76. The company has a market cap of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.99. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analysts' expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, equities research analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after purchasing an additional 645 shares during the period. Millennium Management LLC raised its position in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock worth $16,172,000 after buying an additional 233,873 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of OrthoPediatrics by 112.3% during the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock worth $4,937,000 after acquiring an additional 106,041 shares during the period. Jane Street Group LLC acquired a new stake in OrthoPediatrics in the first quarter valued at about $389,000. Finally, American Century Companies Inc. lifted its position in OrthoPediatrics by 12.5% in the second quarter. American Century Companies Inc. now owns 34,486 shares of the company's stock valued at $741,000 after purchasing an additional 3,828 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. BTIG Research boosted their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Thursday, August 20th. Piper Sandler restated an "overweight" rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC increased their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $26.44.

Key Stories Impacting OrthoPediatrics

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of $26.44, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target
• Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately 6.53 million shares, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing
• Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of 326,700 shares on August 28 at an average price of $23.04, worth approximately $7.53 million. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing
• Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of 10,131 shares on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source